abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
biotech · Huntington Disease · Alzheimer Disease · VYGR
Voyager Therapeutics
Voyager Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Lexington, USA HQ
2014 Founded
168 Employees
Public company Type
VYGR · NYSE Ticker
Company details
- Status
- Public
- HQ
- Lexington, USA
- Founded
- 2014
- Employees
- 168
- Programs
- 4
- Drugs
- 4
- Patents
- 31
Voyager Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Voyager Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Voyager Therapeutics in public FDA and regional records.
-
Development asset linked to Voyager Therapeutics in public FDA and regional records. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor agonist